CT:GUD Knight Therapeutics Inc

Knight Therapeutics Inc., a specialty pharmaceutical company, engages in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada and internationally. The company's commercialized products include Impavido, an alkyllysophospholipid analogue drug for the treatment of visceral and cutaneous Leishmaniasis; Movantik for the treatment of opioid induced constipation; AzaSite to treat bacterial conjunctivitis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Flat Tummy Tea, a herbal detox tea; and FOCUSfactor, a dietary supplement. Its products under development comprise Probuphine to treat opioid addiction; NeurAxon family to treat acute migraine, pain, and neurological disorders; Antibe family to treat chronic pain and inflammation; Iluvien to treat diabetic macular edema; and Netildex to treat ocular inflammation. The company's products under development also include ATryn for the prevention of thromboembolic events; 60P family to treat tropical diseases; Advaxis family to treat HPV-associated cancers and other diseases; FLEXISEQ to treat pain and joint stiffness associated with osteoarthritis; Hand MD, a line of anti-aging hand skincare products; and Crescita family, a line of dermo-cosmetic products. In addition, it finances other life science companies; and invests in life sciences venture capital funds. The company is headquartered in Montreal, Canada.

5.33 CAD
As of 09/29/2022


Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Industry:  Drug Manufacturers-Specialty &
Index country:  Canada
Country of incorporation:  Canada
IPO date:  03/03/2014
Stock exchange:    Toronto Stock Exchange
Exchange country:   Canada
Market cap:   600,655,680 CAD
Current dividend yield:   0.00%
Sedol:      BK6WN77

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy